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Hematopoietic cell transplantation (HCT) using CCR5-D32/D32 stem cells from an adult donor has resulted in
the only known cure of human immunodeﬁciency virus (HIV) infection. However, it is not feasible to repeat
this procedure except rarely because of the low incidence of the CCR5-D32 allele, the availability of only
a small number of potential donors for most patients, and the need for a very close human leukocyte antigen
(HLA) match between adult donors and recipients. In contrast, cord blood (CB) transplantations require
signiﬁcantly less stringent HLA matching. Therefore, our hypothesis is that cure of HIV infections by HCT can
be accomplished much more readily using umbilical CB stem cells obtained from a modestly sized inventory
of cryopreserved CCR5-D32/D32 CB units. To test this hypothesis, we developed a screening program for CB
units and are developing an inventory of CCR5-D32/D32 cryopreserved units available for HCT. Three hundred
such units are projected to provide for white pediatric patients a 73.6% probability of ﬁnding an adequately
HLA matched unit with a cell dose of 2.5  107 total nucleated cells (TNCs)/kg and a 27.9% probability for
white adults. With a cell dose of 1  107 TNCs/kg, the corresponding projected probabilities are 85.6% and
82.1%. The projected probabilities are lower for ethnic minorities. Impetus for using CB HCT was provided by
a transplantation of an adult with acute myelogenous leukemia who was not HIV infected. The HCT was
performed with a CCR5-D32/D32 CB unit, and posttransplantation in vitro studies indicated that the patient’s
peripheral blood mononuclear cells were resistant to HIV infection.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Infection with the human immunodeﬁciency virus type 1
(HIV-1) requires both a CD4 receptor and a chemokine
receptor, principally chemokine receptor 5 (CCR5) [1]. In
humans, the CCR5 protein is encoded by the CCR5 gene
located on the short arm (p) of chromosome 3 at position 21.
Certain populations have inherited the D-32mutation, which
results in the genetic deletion of a portion of the CCR5 gene.
Homozygous carriers of this mutation (CCR5-D32/D32) are
resistant to HIV-1 infection [2-4]. In 2009, Hütter et al. [5]
reported long-term control of HIV infection by hematopoi-
etic cell transplantation (HCT) using peripheral blood stem
cells from a CCR5-D32/D32 donor. More than 5½ years
after this treatment, the patient is still off antiretroviraldgments on page 397.
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different tissue samples, including gut, liver, and brain, no
viral load or proviral DNA could be detected [6]. Allers et al.
[7] reported that these results strongly suggest cure of HIV is
achieved in this patient. Deeks and McCune [8] commented
that “the HIV research community is hesitant to use theword
‘cure,’ but this single case could very well be the ﬁrst
example to ﬁt the bill.”
Although it is compelling, this concept of performing HCT
using stem cells from CCR5-D32/D32 adult donors of bone
marrow or peripheral blood for treatment of HIV-infected
patients cannot be readily generalized. This is true because
the prevalence of the homozygous variant allele is low, that
is, only about .8% to 1% of individuals of northern European
descent have the CCR5-D32/D32 genotype [9,10], and it is
much less prevalent in other ethnic groups [11]. Further-
more, most patients in need of an HCT have only a small
number of potential donors from among registries of adult
donors because a very close human leukocyte antigen (HLA)
match for 8 of 8 or 7 of 8 high-resolution alleles at four lociTransplantation.
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ients [12]. Hütter and Thiel reported no further cases of HCT
for HIV-infected patients because of the inability to match
such patients with adult CCR5-D32/D32 donors despite
a diligent search for “patient number 2” [13], and to date, no
other such patients have been reported.
In marked contrast, HCT using umbilical cord blood does
not require such stringent HLA matching between donor and
recipient [14]. Acceptable HLA-matched units include those
that are matched at 4 of 6, 5 of 6, or 6 of 6 alleles at 3 loci
using low-resolution testing at the A and B loci and high-
resolution testing at the DRB1 locus, disallowing 2
mismatches at the same locus for 4 of 6 matching.
Our hypothesis, therefore, is that cure of HIV by HCT can
be readily accomplished only by using CCR5-D32/D32
umbilical cord blood stem cells. To test this hypothesis, we
developed a cord blood screening program and are devel-
oping an inventory of CCR5-D32/D32 units.
While testing was being performed, one of the units
subsequently found to be CCR5-D32/D32 was discovered to
have been released for HCT for an adult patient with acute
myelogenous leukemia. This provided us the opportunity to
document that a CCR5-D32/D32 cord blood unit resulted in
donor cell engraftment and that the patient’s peripheral
blood mononuclear cells after transplantation were resistant
in vitro to infection with HIV-1.
MATERIALS AND METHODS
Developing an Inventory of CCR5-D32/D32 Cord Blood Units
Samples of cord blood units for testing were primarily from white
donors in the inventories of StemCyte International Cord Blood Center
(hereafter referred to as simply StemCyte) and from numerous collaborating
cord blood banks: St. Louis Cord Blood Bank; Carolinas Cord Blood Bank at
Duke University; University of Colorado Cord Blood Bank; MD Anderson
Cancer Center Cord Blood Bank; the Barcelona, Spain Cord Blood Bank; and
the Sydney, Australia Cord Blood Bank. Samples from collaborating cord
blood banks were sent to StemCyte, usually as about 500 mL of blood from
the pre- or postprocessing sample. DNA is extracted from these samples, and
the DNA specimens were then tested for CCR5-D32 at the City of Hope
Medical Center to determine if the units were homozygous, heterozygous, or
wild type. Some cord blood samples were sent from the collaborating cord
blood banks as DNA.
DNA isolation was carried out using QlAamp DNA Mini and QlAmp DNA
Blood Mini Kits (Qiagen Inc, Valencia, CA). These are designed for puriﬁca-
tion of an average of 6 mg of total DNA from 200 mL of whole human blood
and up to 50 mg of DNA from 200 mL of buffy coat.
Genotype analysis was performed at the City of Hope Medical Center
on DNA preparations (1 mL, 100 ng DNA) extracted from cord blood using a
polymerase chain reaction (PCR)-based assay for homozygosity of CCR5-D32
base pair deletion.
DNA oligonucleotides were purchased from Integrated DNA Technolo-
gies (Integrated DNA Technologies, Coralville, IA).
Primer 1 TTCATTACACCTGCAGCTCTC
Primer 2 CCTGTTAGAGCTACTGCAATTAT
Primer 3 TGCAGCTCTCATTTTCCATACATTA
To identify the CCR5 genes with an internal 32ebase pair deletion
(CCR5-D32 allele), the DNAs were ampliﬁed using a real-time PCR on
a C1000 Thermocycler (BioRad, Bio-Rad Laboratories, Hercules, CA). A total
of 1.5 mL of genomic DNA was used as template, and each PCR was carried
out in a 25-mL volume in 1x SYBR Green supermix (170-8882, Bio-Rad) with
15 pmol each of primer 2 and primer 3 for 3 minutes at 94C (1 cycle); 20
seconds at 94C, 1 minute at 68C (30 cycles); and 7 minutes at 72C (1
cycle).
A second round of PCR was performed on samples that ampliﬁed with
the primer 2 and 3 pairs, which is speciﬁc for the deletion. The second round
used primers 1 and 2, which are positioned outside of the deleted region, to
allow us to discriminate whether the deletions are homozygous or hetero-
zygous. Reaction mixtures consisted of 15 pmol of each primer, 1.5 mL of the
ﬁrst round amplicons, .2 mM dNTP mix, 3 mM MgCl2, and 1U Taq gold DNA
polymerase (Applied Biosystems-Life Technologies, New York, NY) in a total
reaction volume of 25 mL at 95C for 3minutes (1 cycle); 95C for 45 seconds,
60C for 45 seconds, 72C for 45 seconds (40 cycles); and 72C for 7 minutes
(1 cycle). After the PCR ampliﬁcation, the products were separated byelectrophoresis on a 2% agarose gel and visualized by ethidium bromide
staining. The products from deletion-containing samples generate either
a single band of 157 base pair from the homozygous deletions (D32/D2) or
two bands of 189 and 157 base pair from the heterozygous samples.
Projections of the Probability of Finding an Appropriately HLA-Matched
Cord Blood Unit with an Adequate Cell Dose for a Patient in Need of
an HCT
HLAmatch rates for an inventory of 300 CCR5-D32/D32 cord blood units
were estimated with population HLA haplotype frequencies using a pop-
ulation genetic model developed by Kollman and colleagues previously
applied to project match rates for planning the National Cord Blood
Inventory [15,16]. Simulation of HLA genotypes of patients and cord blood
units not yet collected requires the use of HLA haplotype frequencies, which
were calculated at the allele-family level for HLA-A and -B and allele level for
DRB1 in a cohort of 679,519 white European donors from the Be The Match
Registry [17]. We simulated cord blood units using distribution of cord blood
unit total nucleated cells (TNCs) of units banked in the Be The Match
Registry and simulated patients using separate distributions of weights of
pediatric (under age 16 years) and adult (age 16 years and over) patients
who have searched the Be The Match Registry. We incorporated the dose
requirement into the model by calculating the percentage of cords with the
commonly used minimum adequate TNC dose of 2.5  107/kg for each
simulated patient based on his or her weight and considered matched units
with inadequate dose as unavailable. The simulated HLA genotypes con-
sisted of a pool of 10,000 simulated European-American patients searching
10 replicate simulated European-American 300-unit cord blood unit
inventories, with reported match rates averaged over the results from the
10 inventories. This model assumes that HLA haplotypes in patients and
CCR5-D32/D32 variant cords are drawn from the same overall European-
American HLA frequency distribution. However, because the geographic
distribution of the CCR5 variant is centered over Northern Europe [18], the
HLA match rates for European-American patients are slightly higher than
the projection if the patient has Northern European ancestry and lower if
the patient has Southern European ancestry.
The CCR5-D32/D32 units in the special inventory are primarily from
white donors, and it is true that patients in need of transplantation more
commonly ﬁnd a matched donor from among those in their own ethnic
group. However, this is not invariably true, and HLA matched donors are not
uncommonly found among those in other ethnic groups. To assess match
rates for minority populations, we simulated 10,000 African American,
Mexican Hispanic, and Chinese American patients searching European-
origin cord inventory replicates.
Recent data indicate that a minimum cord blood cell dose of 1 x 107
TNCs/kg body weight is adequate when a combined haploidentical and cord
blood transplantation is performed [19]. Accordingly, similar projections
were also carried out using this minimum cell dose.
Testing the Cells In Vitro of a Patient with Acute Myelogenous Leukemia
Who underwent Transplantation with CCR5-D32/D32 Cord Blood Stem
Cells for Resistance to HIV Infection with Laboratory Strains BAL and
NL4-3
Peripheral blood samples were collected from an HIV-negative patient
with acute myelogenous leukemia on day þ123 post-HCT at a time when
chimerism studies indicated complete engraftment by CCR5-D32/D32 cells.
The cells were cryopreserved and, when thawed, were shown to have >90%
viability by trypan blue exclusion and 7- amino-actinomycin D ﬂow
cytometry. The Ficoll-hypaqueeseparated peripheral blood mononuclear
cells from the transplantation recipient, a normal adult control, and CCR5-
D32 heterozygous and homozygous cord blood units were tested for
susceptibility to infection with the laboratory strains HIV1 BAL, and the
transplantation recipient’s peripheral blood mononuclear cells were also
infected with NL4-3 at multiplicity of infection of .01 in vitro after standard
phytohemagglutinin stimulation. Supernatants were collected and
measured for p24Ag (Perkin-Elmer, Inc, Waltham, MA ) at 3 and 7 days
postinfection. No additional peripheral bloodmononuclear cells were added
to cultures during the 7-day incubation. Patient cells were tested for CCR5-
D32/D32 chimerism and again for viability by 7-amino-actinomycin D by
ﬂow cytometry at the termination of the experiment.
RESULTS
Identifying CCR5-D32/D32 Units in Inventories of
Cryopreserved Cord Blood Units
Thus far, we have identiﬁed 134 cord blood units that are
CCR5-D32/D32s after having tested approximately 18,000
units, primarily from white patients, for an incidence of
approximately .7%. In addition, we searched 8,000 Asian
Table 1
Projected HLA Match Rates with a 300-Unit Inventory of CCR5-D32/D32
Cord Blood Units
Ethnic Group Adult Patients Pediatric Patients
Whites Includes need for TNCs of 2.5  107 cells/kg
6 of 6 matches: .01% 6 of 6 matches: .01%
5 of 6 matches: 4.5% 5 of 6 matches: 10.6%
4 of 6 matches: 27.9% 4 of 6 matches: 73.6%
Includes need for TNCs of 1  107 cells/kg
6 of 6 matches: .09% 6 of 6 matches: 1.01%
5 of 6 matches: 10.7% 5 of 6 matches: 10.8%
4 of 6 matches: 82.1% 4 of 6 matches: 85.6%
Minority Includes need for TNCs of 2.5  107 cells/kg
African American 4 of 6 matches: 9.9% 4 of 6 matches: 28.6%
Mexican American 4 of 6 matches: 14% 4 of 6 matches: 44.1%
Chinese American 4 of 6 matches: 2.7% 4 of 6 matches: 12.3%
Includes need for TNCs of 1  107 cells/kg
African American 4 of 6 matches: 31.6% 4 of 6 matches: 34.1%
Mexican American 4 of 6 matches: 48.9% 4 of 6 matches: 52.5%
Chinese American 4 of 6 matches: 13.9% 4 of 6 matches: 15.7%
TNC indicates total nucleated cell.
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homozygous units. Testing of an additional approximately
25,000 cord blood units from whites is expected to increase
the special inventory to about 300 units.
Probabilities of Finding Adequately Matched Cord Blood
Units with an Adequate Cell Dose in an Inventory of 300
CCR5-D32/D32 Cord Blood Units
Table 1 indicates the projected probabilities of ﬁnding an
adequately HLA-matched unit with a TNC count of
2.5  107/kg or with a TNC count of 1 107 cells/kg in an
inventory of 300 CCR5-D32/D32 units for pediatric and adult
white patients and for patients of other ethnic groups. Pro-
jected match rates for white patients using a minimum
necessary TNC count of 2.5  107/kg were 73.6% for pedi-
atric patients and 27.9% for adults. Using a minimum
necessary TNC count of 1.0  107/kg, the projected match
rates were 82.1% for adults and 85.6% for pediatric patients.
Probable match rates were signiﬁcantly lower for patients of
minority ethnic groups (Table 1).
Testing the Cells of the Patient Who underwent
Transplantation with a CCR5-D32/D32 Unit for
Resistance to HIV Infection
As seen in Figure 1A, the recipient’s peripheral blood
mononuclear cells on day þ123 showed no signiﬁcant HIV
replicationwith in vitro infectionwith either of the laboratory
strains of HIV1, BAL (CCR5 tropic), or NL4-3 (CXCR4)
compared with a normal control. Figure 1B shows a compar-
ison ofHIV replication in vitrowith the laboratoryCCR5 strain
HIV-1BAL for cord blood peripheral blood mononuclear cells
from CCR5 wild-type, heterozygous, and homozygous units.
There was no detectable HIV replication in vitro in the CCR5-
D32/D32 cord blood cells compared with signiﬁcant replica-
tion in the heterozygous and wild-type cord blood cells.
DISCUSSION
Long-term control of HIV infection has been accom-
plished by Hütter et al. [5] with HCT using peripheral blood
stem cells from a CCR5-D32/D32ematched unrelated adult
donor. The patient has remained without any evidence of
HIV infection for more than 5½ years after discontinuation
of antiretroviral drug therapy [13]. However, using CCR5-
D32/D32 stem cells from adult donors in bone marrow or
peripheral blood stem cell transplantations cannot be readily
generalized as a treatment option because of the rarity of thevariant allele and the need for a very close HLA match
between recipient and donor. As noted, the unsuccessful
attempt by Hütter et al. to perform an HCT for a second
patient conﬁrms the futility of this approach [13]. In contrast,
umbilical cord blood transplantations require signiﬁcantly
less stringent requirements for HLA matching.
Accordingly, our hypothesis is that cure of HIV infections
by HCT can be much more readily accomplished using
umbilical cord blood stem cells obtained from a modestly
sized inventory of cryopreserved CCR5-D32/D32 cord blood
units. Furthermore, the numerous reports of essentially
equivalent posttransplantation outcomes using cord blood as
compared with the results of bone marrow and peripheral
blood cell transplantations lend impetus to this approach
[20-26]. Despite these reports, there are plentiful data indi-
cating that cord blood transplantation is signiﬁcantly
underutilized [27]. Starting in 2003, StemCyte cord blood
inventories were screened for CCR5-D32/D32 donors.
In addition, the transplantation of a CCR5-D32/D32 cord
blood unit to an adult patient with acute myelogenous
leukemia as part of a double cord blood transplantation
provided the opportunity to collect data that indicated
engraftment of the CCR5-D32/D32 unit as the dominant unit.
At a time when chimerism studies indicated 100% engraft-
ment by the CCR5-D32/D32 unit, in vitro studies indicated
that the patient’s peripheral blood mononuclear cells were
resistant to HIV1 BAL and NL4-3 strains (Figure 1A, B).
Projections regarding the probability of ﬁnding an appro-
priately HLA-matched unit with an adequate cell dose for
a white patient using a population of simulated patients are
based on theHLA frequencieswithin the USwhite population
and the cell doses of units presently in the special inventory.
We arbitrarily chose an inventory of 300 CCR5-D32/D32 units
for our initial calculations and are developing such an inven-
tory. Collaboration among numerous cord blood banksmakes
the development of a special inventory of this size eminently
feasible, and, if needed, additional units can readily be added.
Gonzales et al. [11] estimated that there are approximately
400,000 cord blood units cryopreserved around the globe,
among them 2,000 to 4,000 CCR5-D32/D32 units.
The projections took into consideration the need for an
adequate cell dose, which is generally accepted to be in the
range of2.5 107 TNCs/kg. The projections indicate that an
inventory of 300 units would provide a 73.6% probability of
ﬁnding an adequately HLA-matched unit for white pediatric
patients and a probability of 27.9% for white adult patients
(Table 1). Also, since Liu et al. [19] reported that a cord blood
cell dose as lowas1107 TNCs/kgbodyweight is adequate for
cord blood transplantations done in association with
a haploidentical transplantation, we have made projections
using this as the minimum necessary cell dose. These
projections indicate the probability of ﬁnding an adequately
HLA-matched unit for 85.6% of white pediatric patients and
82.1% for white adult patients (Table 1). The use of combined
haploidentical and cord blood transplantations [19] provides
important, and probably essential, advantages when consid-
ering use of cord blood transplantation to cure HIV in adults.
Finding two adequately matched units from an inventory of
300 cord blood units would be very problematic, whereas the
use of a single cordbloodunit combinedwith ahaploidentical
transplantation is much more feasible. Further, in such
transplantations, engraftment is rapid, and chimerismstudies
have shown that cells from the cord blood unit almost always
are the only ones present severalmonths posttransplantation
[19].However, itmustbenoted that combinedhaploidenticale
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Figure 1. (A) In vitro study of infectivity by HIV-1 of peripheral blood mononuclear cells (PBMCs) in the posttransplantation period from an HIV-uninfected patient
who underwent transplantation with a CCR5-D32/D32 cord blood. The recipient’s PBMCs showed no signiﬁcant infection with either lab strains of HIV-1, BAL (CCR
tropic), or NL4e3 (CXCR4) compared with a normal adult control. (B) A comparison of HIV replication in vitro with the laboratory CCR5 strain HIV-1 BAL for cord
blood PBMCs from normal CCR5 wild-type, heterozygous, and homozygous units. There was no detectable replication in vitro in the CCR5-D32/D32 cord cells
compared with signiﬁcant replication in the heterozygote and wild-type cord cells.
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this time in the United States, and the adequacy of a cell dose
of 1 107TNCs/kg has not yet been conﬁrmed.
To assess match rates for minority populations, we
simulated 10,000 African American, Mexican Hispanic, and
Chinese American patients searching European-origin cord
inventory replicates. As expected, the projected probabilities
are signiﬁcantly lower (Table 1).
The most obvious patient population for the trans-
plantation of CCR5-D32/D32 cord blood units is that group of
patients who are in need of an HCT for a hematological
malignancy or other indication and are also infected with
HIV. The incidence of patients meeting these criteria has not
been determined and would appear to be relatively small.
However, Hütter and Zaia [28] pointed out that “the lifetime
expectancy of HIV-infected patients has improved substan-
tially, but nevertheless the incidence rate of malignancies in
these patients has increased considerably. Therefore, it can
be assumed that there will be a rising necessity for HIV-1
infected patients with malignancies for allogeneic HCT.”
Krishnan and Forman also indicate that the incidence of
Hodgkin’s lymphoma and non-Hodgkin’s lymphoma is
increased in HIV-infected patients compared with the
general population [29]. AIDS-related malignancies remain
a leading cause of mortality in HIV-infected patients [30].
Many physicians still automatically consider HIV status
a barrier to transplantation, and transplant centers often
exclude these patients from their protocols [30]. However,experience during the last 25 years indicates successful HCT
in HIV-infected patients with hematological disease,
including not only leukemia and relapsed lymphoma but also
successful treatment of nonmalignant disorders such as
aplastic anemia [28]. The outcome of allografted HIV-
positive patients is probably only negligibly poorer in
comparison with HIV-negative patients [28].
An alternative approach to cure of HIV infection is offered
by CCR5-targeted gene therapy of either T cells or stem cells,
using siRNA-based therapeutics, as recently reported
[8,29,31-33]. Another highly innovative approach relies on
engineered zinc ﬁnger nucleases speciﬁc for the CCR5 gene
[34]. Zinc ﬁnger nucleases are a powerful tool that can be
used to edit the human genome ad libitum [35]. The tech-
nology has experienced remarkable development in the last
few years with regard to both the target site speciﬁcity and
the engineering platforms used to generate zinc ﬁnger
proteins [35]. To date, clinical beneﬁt has not been demon-
strated in clinical trials [32], but recent progress in the ﬁeld
provides optimism that some of the promises of gene
therapy may ﬁnally be realized [36,37].
In addition to HCT for HIV-infected patients with
a hematological malignancy or other indication for trans-
plantation, selected patients with AIDS who have no other
illness should also be considered for a clinical trial of CCR5-
D32/D32 cord blood transplantation. The optimism of
antiretroviral treatment is dampened by the current impos-
sibility of viral eradication, the sustained medication with
L.D. Petz et al. / Biol Blood Marrow Transplant 19 (2013) 393e397 397complex regimens, the potential toxic effects, and the prev-
alence of drug-resistant isolates [38]. Patients with AIDS who
are responding poorly to antiretroviral regimens and are
informed of the signiﬁcant risks of HCT and the potential
beneﬁts should be allowed to participate in a clinical trial of
HCT if an appropriately HLA-matched CCR5-D32/D32 unit of
adequate cell dose is available.
The seemingly logical approach to a cure using adults who
volunteer to be bone marrow/peripheral blood donors and
who are found to have the variant CCR5 allele is an improb-
able solution. The testing for CCR5-D32/D32 at the time
donors are registered with the National Marrow Donor
Program is expensive and not likely to be effective because of
the statistical improbability of ﬁnding both the high-grade
HLA match, as is required when HCT is done using stem
cells from adults, and a CCR5-D32/D32 genotype in the donor.
Thus, it is more reasonable to suggest large-scale testing of
newly donated and currently inventoried cord blood for
CCR5-D32/D32 units.
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